OneSkin

Protein turnover is correlated to lifespan

Latest articles

Exclusive video interview with Erin Sharoni of JUVICELL

We talk fasting, lifespan and longevity supplements with JUVICELL's co-founder, Erin Sharoni. Recently, we were excited to cover the launch of brand-new longevity supplement JUVICELL,...

Longevity supplement innovator soft-closes $5.5m

Ponce de Leon: the longevity supplement company behind Rejuvant could raise up to $15m in current series B round. Ponce de Leon Health, a company...

Swiss longevity company builder launches

Swiss-based Maximon already moving forward with companies focused on precision supplements and personalised longevity advice. Already touted as a hotbed of longevity innovation, Switzerland is...

New aging clock is a key longevity tool

A new aging clock that's close to the theoretical limit of accuracy boasts unprecedented precision and offers new insights into how the aging process...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Apollo Neuro

Editor's picks

Exclusive video interview with Erin Sharoni of JUVICELL

We talk fasting, lifespan and longevity supplements with JUVICELL's co-founder, Erin Sharoni. Recently, we were excited to cover the launch of brand-new longevity supplement JUVICELL,...

Longevity supplement innovator soft-closes $5.5m

Ponce de Leon: the longevity supplement company behind Rejuvant could raise up to $15m in current series B round. Ponce de Leon Health, a company...

Swiss longevity company builder launches

Swiss-based Maximon already moving forward with companies focused on precision supplements and personalised longevity advice. Already touted as a hotbed of longevity innovation, Switzerland is...
OneSkin

Protein turnover decreases with age to preserve metabolic costs, especially in longer-lived organisms including humans.

Proteostasis is the dynamic regulation of proteins in order to ensure proper synthesis, folding and degradation in an organism. Every protein has a certain lifetime ranging from minutes to years. After a period of time, a protein is degraded and replaced by a newly synthesised version. This cellular process is known as protein turnover (PTO).

Longevity.Technology: The PTO of a protein generally depends on the cell type, organism and a plethora of environmental factors. On a cellular level, specific genetic motifs, protein folding state and cellular proteolytic pathways involved define PTO rate.

There are two general protein degradation pathway classes: constitutive and specific. The constitutive pathway removes proteins through a basal level of autophagy and is a general mechanism. Specific pathways are more intricate mechanisms to efficiently sense and remove proteins.

Whilst more efficient, specific protein degradation pathways are energetically more costly, charging in the universal cellular energy currency – ATP. A by-product of ATP synthesis is the production of radical oxygen species, which lead to damaging consequences including DNA damage and cancer.

Within the Longevity field, there is significant interest in understanding the relationship between changes in PTO, its kinetics and proteostatic distribution during aging. There is evidence suggesting that slower PTO rates may be associated with lower protein quality control and diminished proteostasis during aging [1].

A study on C. elegans found that knocking-out the insulin-like growth factor 1 receptor increases global PTO rates and artificially extends lifespan [2]. Whether the relationship is causal or casual was not defined.

There are a handful of contradicting studies that use mammalian model systems that found that when extending lifespan through diet, therapeutic and genetic modification PTO rates decrease [3].

The relationship between PTO and Longevity is complex and enigmatic. Professor Sina Ghaemmaghami from the University of Rochester has conducted a comparative proteomic study on rodent species that showed that “longevity was correlated with slower rates of in vitro protein turnover” [4].

To explore literature discrepancies the team expanded their study to include 12 distinct species with lifespans spanning from 4 years to 200 years, the latter belonging to the bowhead whale.

A proteome-wide analysis was conducted on skin fibroblast cells through Stable Isotope Labelling in Cell Culture (SILAC). Precision of all measurements was validated through repeats and distribution of shared known proteins between species considered.

 


 

“Finding a protein as a marker for aging could allow a better monitoring of biological age, aid in aging clocks development and the understanding Longevity…”

 


 

After phylogenetic corrections, key comparisons lead to the conclusion that the longer the lifespan the more decreased PTO is observed. Interestingly, more abundant proteins, such as ribosomal protein 26, are diminished to a more notable extent.

Furthermore, the biologists developed a quantitative measure of lifespan dependence based on the turnover-lifespan slope (TLS). Cytosolic and endoplasmic reticulum proteins showed a low TLS value, thus a more negative slope. In this case, the longer the lifespan of the organism the slower the PTO. Membrane bound and vesicle localised proteins had high TLS values, thus the longer the lifespan the less significant the decrease in PTO, but a decrease nonetheless.

Which mode of protein degradation, basal or specific – nonselective or selective – dominates may be key to the discrepancies found in the literature. The model used to study Longevity and PTO may have different patterns of protein regulation.

Professor Ghaemmaghami speculates: “If nonselective PTO plays a more prominent role in proteostasis in shorter lived organisms, it is understandable why extending lifespan may require faster rates of total protein flux [5].” On the other, organisms with longer lifespans, including mammals, have increased ROS levels increasing over time acting as an impetus for increase PTO. Lifespan extension is likely to be associated with the lower energetic demands of slow PTO.

Hence the results of the study “support the idea that the beneficial effects of PTO on proteostasis and longevity are mitigated by metabolic costs” [5]. Finding a protein as a marker for aging could allow a better monitoring of biological age, aid in aging clocks development and the understanding of Longevity.

[1] https://www.nature.com/articles/nm.4001
[2] https://pubmed.ncbi.nlm.nih.gov/18006689/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4547605/
[4] https://pubmed.ncbi.nlm.nih.gov/27248575/
[5] https://www.mcponline.org/article/S1535-9476(20)35170-7/fulltext

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
OneSkin

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...

NAD+ and metformin: AgelessRx’s anti-aging platform

Personalised longevity medicine is the top goal for AgelessRx. In November we spoke to Anar Isman, the Co-founder & CEO of AgelessRx, about PEARL, the...
Apollo Neuro

Related articles

Plastic surgery in-a-box: a cryo biotech innovation

Future-facing Uvence is innovating for the future of your face. The biotech market is growing, as coverage on Longevity.Technology evidences. The ripples of biotech innovation...

AgeX and LyGenesis to negotiate merger agreement

The biotech merger between AgeX and LyGenesis will neaten-up Juvenescence's portfolio. AgeX Therapeutics, a biotech developing therapeutics for human aging and cell regeneration, and LyGenesis,...

Rejuvenate Biomed bags €3.2m for healthy aging R&D

Belgium biotech secures €3.2m Series A to advance the development of healthy aging products. Rejuvenate Biomed, which is based in Antwerp, has announced it has...

OneSkin: turning back time for your skin

Skin rejuvenating cream goes more than skin deep with senotherapeutic treatment. Last year we reported on the launch of OneSkin, a topical senotherapeutic skin treatment...

BioAge kicks off Phase 2 longevity clinical trial

Company reveals primary indicator for BGE-117 clinical trial is unexplained anaemia of aging. Hot on the heels of its monster $90 million Series C funding...
OneSkin